Quimioterapia individualizada o modificada (ajuste o retraso de la dosis)

Corsetti MT, Salvi F, Perticone S, Baraldi A, De Paoli L, Gatto S, Pietrasanta D, Pini M, Primon V, Zallio F, Tonso A, Alvaro MG, Ciravegna G, Levis A.

Fuente‎: Leuk Res 2011;35(8):991-7.

Indexado en‎: PubMed 21474179

DOI‎: 10.1016/j.leukres.2011.02.021

https://www.ncbi.nlm.nih.gov/pubmed/21474179 (abre una nueva ventana)

Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. (abre una nueva ventana)

Coutre SE, Othus M, Powell B, Willman CL, Stock W, Paietta E, Levitan D, Wetzler M, Attar EC, Altman JK, Gore SD, Maher T, Kopecky KJ, Tallman MS, Larson RA, Appelbaum FR.

Fuente‎: Br J Haematol 2014;165(4):497-503.

Indexado en‎: PubMed 24528179

DOI‎: 10.1111/bjh.12775

https://www.ncbi.nlm.nih.gov/pubmed/24528179 (abre una nueva ventana)

Low-dose cytosine arabinoside as an alternative treatment for acute leukemia in Jehovah's Witnesses. (abre una nueva ventana)

Dainer PM, Knupp CL, Sartiano GP.

Fuente‎: Am J Hematol 1992;40(2):156-7.

Indexado en‎: PubMed 1585917

https://www.ncbi.nlm.nih.gov/pubmed/1585917 (abre una nueva ventana)

Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. (abre una nueva ventana)

Delarue R, Tilly H, Mounier N, Petrella T, Salles G, Thieblemont C, Bologna S, Ghesquières H, Hacini M, Fruchart C, Ysebaert L, Fermé C, Casasnovas O, Van Hoof A, Thyss A, Delmer A, Fitoussi O, Molina TJ, Haioun C, Bosly A.

Fuente‎: Lancet Oncol 2013;14(6):525-33.

Indexado en‎: PubMed 23578722

DOI‎: 10.1016/S1470-2045(13)70122-0

https://www.ncbi.nlm.nih.gov/pubmed/23578722 (abre una nueva ventana)

Azacitidine and venetoclax in previously untreated acute myeloid leukemia. (abre una nueva ventana)

DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, Döhner H, Letai A, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, Pejsa V, Hájek R, Porkka K, Illés Á, Lavie D, Lemoli RM, Yamamoto K, Yoon SS, Jang JH, Yeh SP, Turgut M, Hong WJ, Zhou Y, Potluri J, Pratz KW

Fuente‎: N Engl J Med 2020;383(7):617-29.

Indexado en‎: PubMed 32786187

DOI‎: 10.1056/NEJMoa2012971

https://www.ncbi.nlm.nih.gov/pubmed/32786187 (abre una nueva ventana)

Treatment of acute leukaemia in adult Jehovah's Witnesses. (abre una nueva ventana)

El Chaer F, Ballen KK

Fuente‎: Br J Haematol 2020;190(5):696-707.

Indexado en‎: PubMed 31693175

DOI‎: 10.1111/bjh.16284

https://www.ncbi.nlm.nih.gov/pubmed/31693175 (abre una nueva ventana)

Minimally-myelosuppressive asparaginase-containing induction regimen for treatment of a Jehovah's Witness with mutant IDH1/NPM1/NRAS acute myeloid leukemia. (abre una nueva ventana)

Emadi A, Bade NA, Stevenson B, Singh Z.

Fuente‎: Pharmaceuticals (Basel) 2016;9(1):E12.

Indexado en‎: PubMed 27064021

DOI‎: 10.3390/ph9010012

https://www.ncbi.nlm.nih.gov/pubmed/27064021 (abre una nueva ventana)

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. (abre una nueva ventana)

Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T.

Fuente‎: J Clin Oncol 2009;27(28):4733-40.

Indexado en‎: PubMed 19720927

DOI‎: 10.1200/JCO.2008.19.8721

https://www.ncbi.nlm.nih.gov/pubmed/19720927 (abre una nueva ventana)

Successful treatment of a Jehovah's Witness with acute promyelocytic leukemia. (abre una nueva ventana)

Fujita H, Maruta A, Koharazawa H, Hattori M, Tomit N, Kodama F, Mohri H, Okubo T.

Fuente‎: Int J Hematol 1997;65(4):415-6.

Indexado en‎: PubMed 9195782

https://www.ncbi.nlm.nih.gov/pubmed/9195782 (abre una nueva ventana)

Induction with azacytidine followed by allogeneic hematopoietic stem cell transplantation in a Jehovah's Witness with acute monocytic leukemia. (abre una nueva ventana)

Garelius H, Grund S, Stockelberg D.

Fuente‎: Clin Case Rep 2015;3(5):287-90.

Indexado en‎: PubMed 25984306

https://www.ncbi.nlm.nih.gov/pubmed/25984306 (abre una nueva ventana)

Immediate or delayed therapy with 2-CdA for hairy cell leukemia in Jehova's Witness? (abre una nueva ventana)

Juliusson G.

Fuente‎: Am J Hematol 1996;53(1):49.

Indexado en‎: PubMed 8813099

DOI‎: 10.1002/(SICI)1096-8652(199609)53:1<49::AID-AJH12>3.0.CO;2-Z

https://www.ncbi.nlm.nih.gov/pubmed/8813099 (abre una nueva ventana)

Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treat. (abre una nueva ventana)

Laszlo D, Agazzi A, Goldhirsch A, Cinieri S, Bertolini F, Rabascio C, Pruneri G, Calabrese L, Cocquio A, Martinelli G.

Fuente‎: Eur J Haematol 2004;72(4):264-7.

Indexado en‎: PubMed 15089764

DOI‎: 10.1111/j.0902-4441.2003.00211.x

https://www.ncbi.nlm.nih.gov/pubmed/15089764 (abre una nueva ventana)

Successful treatment of acute promyelocytic leukemia in a pregnant Jehovah's Witness with all-trans retinoic acid, rhG-CSF, and erythropoietin. (abre una nueva ventana)

Lin CP, Huang MJ, Liu HJ, Chang IY, Tsai CH.

Fuente‎: Am J Hematol 1996;51(3):251-2.

Indexado en‎: PubMed 8619417

DOI‎: 10.1002/(SICI)1096-8652(199603)51:3<251::AID-AJH20>3.0.CO;2-I

https://www.ncbi.nlm.nih.gov/pubmed/8619417 (abre una nueva ventana)

Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia. (abre una nueva ventana)

Lou Y, Qian W, Meng H, Mai W, Tong H, Tong Y, Huang J, Jin J.

Fuente‎: Hematol Oncol 2014;32(1):40-6.

Indexado en‎: PubMed 23963734

DOI‎: 10.1002/hon.2076

https://www.ncbi.nlm.nih.gov/pubmed/23963734 (abre una nueva ventana)

Cytarabine dose for acute myeloid leukemia. (abre una nueva ventana)

Löwenberg B, Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Biemond BJ, Gratwohl A, de Greef GE, Verdonck LF, Schaafsma MR, Gregor M, Theobald M, Schanz U, Maertens J, Ossenkoppele GJ; Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group.

Fuente‎: N Engl J Med 2011;364(11):1027-36.

Indexado en‎: PubMed 21410371

DOI‎: 10.1056/NEJMoa1010222

https://www.ncbi.nlm.nih.gov/pubmed/21410371 (abre una nueva ventana)

Myeloablative therapy and bone marrow transplantation in Jehovah's Witnesses with malignancies: single center experience. (abre una nueva ventana)

Mazza P, Prudenzano A, Amurri B, Palazzo G, Pisapia G, Stani L, Pricolo G.

Fuente‎: Bone Marrow Transplant 2003;32(4):433-6.

Indexado en‎: PubMed 12900781

DOI‎: 10.1038/sj.bmt.1704179

https://www.ncbi.nlm.nih.gov/pubmed/12900781 (abre una nueva ventana)

Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. (abre una nueva ventana)

Montesinos P, Recher C, Vives S, Zarzycka E, Wang J, Bertani G, Heuser M, Calado RT, Schuh AC, Yeh SP, Daigle SR, Hui J, Pandya SS, Gianolio DA, de Botton S, Döhner H

Fuente‎: N Engl J Med. 2022;386(16):1519-31.

Indexado en‎: PubMed 35443108

DOI‎: 10.1056/NEJMoa2117344

https://pubmed.ncbi.nlm.nih.gov/35443108/ (abre una nueva ventana)

Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer. (abre una nueva ventana)

Nagel CI, Backes FJ, Hade EM, Cohn DE, Eisenhauer EL, O'Malley DM, Fowler JM, Copeland LJ, Salani R.

Fuente‎: Gynecol Oncol 2012;124(2):221-4.

Indexado en‎: PubMed 22055764

DOI‎: 10.1016/j.ygyno.2011.10.003

https://www.ncbi.nlm.nih.gov/pubmed/22055764 (abre una nueva ventana)

The treatment of acute lymphoblastic leukemia in Jehovah's Witnesses and patients who cannot accept blood products. (abre una nueva ventana)

Nguyen N, Madarang E, Alencar A, Watts J, Bradley T

Fuente‎: Leuk Res Rep. 2022 25;18:100355.

Indexado en‎: PubMed 36338830

DOI‎: 10.1016/j.lrr.2022.100355

https://pubmed.ncbi.nlm.nih.gov/36338830/ (abre una nueva ventana)

Developing a blood conservation care plan for Jehovah's Witness patients with malignant disease. (abre una nueva ventana)

Norfolk DR, Wade P, Carter R.

Fuente‎: Presented at the British Society for Haematology 47th Annual Scientific Meeting, Bournemouth [UK] April 2007.

https://www.transfusionguidelines.org/document-library/documents/developing-a-blood-conservation-care-plan-for-jehovah-s-witness-patients-with-malignant-disease/download-file/bbt-JW-Care-Plan-Malignant-Disease-2012.pdf (abre una nueva ventana)

High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors. (abre una nueva ventana)

Perol L, Grignano E, Contejean A, Gastaud L, Legoff M, Franchi P, Deau-Fischer B, Willems L, Bouscary D, Tamburini J

Fuente‎: Leuk Lymphoma. 2019;60(9):2324-7.

Indexado en‎: PubMed 30773115

DOI‎: 10.1080/10428194.2019.1577414

https://www.ncbi.nlm.nih.gov/pubmed/30773115 (abre una nueva ventana)

Hematopoietic growth factors: personalization of risks and benefits. (abre una nueva ventana)

Puhalla S, Bhattacharya S, Davidson NE.

Fuente‎: Mol Oncol 2012;6(2):237-41.

Indexado en‎: PubMed 22497867

DOI‎: 10.1016/j.molonc.2012.03.001

https://www.ncbi.nlm.nih.gov/pubmed/22497867 (abre una nueva ventana)

Bloodless chimeric antigen receptor (CAR) T-cell therapy in Jehovah's Witnesses. (abre una nueva ventana)

Riedell PA, Wu M, Collins JM, Gideon JM, Jakubowiak AJ, Kline JP, Kosuri S, Liu H, Smith SM, Bishop MR

Fuente‎: Leuk Lymphoma 2021;62(6):1497-501.

Indexado en‎: PubMed 33535838

DOI‎: 10.1080/10428194.2021.1876868

https://www.ncbi.nlm.nih.gov/pubmed/33535838 (abre una nueva ventana)

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. (abre una nueva ventana)

Roboz GJ, DiNardo CD, Stein EM, de Botton S, Mims AS, Prince GT, Altman JK, Arellano ML, Donnellan W, Erba HP, Mannis GN, Pollyea DA, Stein AS, Uy GL, Watts JM, Fathi AT, Kantarjian HM, Tallman MS, Choe S, Dai D, Fan B, Wang H, Zhang V, Yen KE, Kapsalis SM, Hickman D, Liu H, Agresta SV, Wu B, Attar EC, Stone RM

Fuente‎: Blood 2020;135(7):463-71.

Indexado en‎: PubMed 31841594

DOI‎: 10.1182/blood.2019002140

https://www.ncbi.nlm.nih.gov/pubmed/31841594 (abre una nueva ventana)

Bloodless (transfusion-free) hematopoietic stem cell transplants: the Mexican experience. (abre una nueva ventana)

Ruiz-Argüelles GJ, Morales-Toquero A, López-Martínez B, Tarín-Arzaga LD, Manzano C.

Fuente‎: Bone Marrow Transplant 2005;36(8):715-20.

Indexado en‎: PubMed 16113672

DOI‎: 10.1038/sj.bmt.1705126

https://www.ncbi.nlm.nih.gov/pubmed/16113672 (abre una nueva ventana)

A Mexican way to cope with stem cell grafting. (abre una nueva ventana)

Ruiz-Delgado GJ, Ruiz-Argüelles GJ.

Fuente‎: Hematology 2012;17 Suppl 1:S195-7.

Indexado en‎: PubMed 22507819

DOI‎: 10.1179/102453312X13336169157130

https://www.ncbi.nlm.nih.gov/pubmed/22507819 (abre una nueva ventana)

Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. (abre una nueva ventana)

Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, Naoe T, Lengfelder E, Büchner T, Döhner H, Burnett AK, Lo-Coco F.

Fuente‎: Blood 2009;113(9):1875-91.

Indexado en‎: PubMed 18812465

DOI‎: 10.1182/blood-2008-04-150250

https://www.ncbi.nlm.nih.gov/pubmed/18812465 (abre una nueva ventana)

SCT in Jehovah's Witnesses: the bloodless transplant. (abre una nueva ventana)

Sloan JM, Ballen K.

Fuente‎: Bone Marrow Transplant 2008;41(10):837-44.

Indexado en‎: PubMed 18246110

DOI‎: 10.1038/bmt.2008.5

https://www.ncbi.nlm.nih.gov/pubmed/18246110 (abre una nueva ventana)

Treatment of acute myelogenous leukemia with outpatient azacitidine. (abre una nueva ventana)

Sudan N, Rossetti JM, Shadduck RK, Latsko J, Lech JA, Kaplan RB, Kennedy M, Gryn JF, Faroun Y, Lister J.

Fuente‎: Cancer 2006;107(8):1839-43.

Indexado en‎: PubMed 16967444

DOI‎: 10.1002/cncr.22204

https://www.ncbi.nlm.nih.gov/pubmed/16967444 (abre una nueva ventana)

Isolated limb perfusion for an irresectable melanoma recurrence in a Jehovah's Witness. (abre una nueva ventana)

van Akkooi AC, Golab-Schwarz HD, Eggermont AM, van Geel AN.

Fuente‎: Eur J Cardiothorac Surg 2006;30(2):408-10.

Indexado en‎: PubMed 16829108

DOI‎: 10.1016/j.ejcts.2006.04.020

https://www.ncbi.nlm.nih.gov/pubmed/16829108 (abre una nueva ventana)

Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. (abre una nueva ventana)

Verstovsek S, Gotlib J, Gupta V, Atallah E, Mascarenhas J, Quintas-Cardama A, Sun W, Sarlis NJ, Sandor V, Levy RS, Kantarjian HM, Mesa RA.

Fuente‎: Onco Targets Ther 2013;7:13-21.

Indexado en‎: PubMed 24368888

DOI‎: 10.2147/OTT.S53348

https://www.ncbi.nlm.nih.gov/pubmed/24368888 (abre una nueva ventana)

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. (abre una nueva ventana)

Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS.

Fuente‎: J Clin Oncol 2007;25(30):4722-9.

Indexado en‎: PubMed 17947719

DOI‎: 10.1200/JCO.2007.12.2440

https://www.ncbi.nlm.nih.gov/pubmed/17947719 (abre una nueva ventana)

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. (abre una nueva ventana)

Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, Kim I, Stevens DA, Fiedler W, Pagoni M, Samoilova O, Hu Y, Anagnostopoulos A, Bergeron J, Hou JZ, Murthy V, Yamauchi T, McDonald A, Chyla B, Gopalakrishnan S, Jiang Q, Mendes W, Hayslip J, Panayiotidis P

Fuente‎: Blood 2020;135(24):2137-45.

Indexado en‎: PubMed 32219442

DOI‎: 10.1182/blood.2020004856

https://www.ncbi.nlm.nih.gov/pubmed/32219442 (abre una nueva ventana)